Sepp-Lorenzino Laura
SEC insider (Form 3/4/5 filer). CIK 0001777421. Director at Taysha Gene Therapies, Inc. (TSHA) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 1, 2026. Located in DALLAS, TX.
Companies Sepp-Lorenzino Laura has filed insider reports for
- Taysha Gene Therapies, Inc. (TSHA): Director
- Lexeo Therapeutics, Inc. (LXEO): Director
- Intellia Therapeutics, Inc. (NTLA): Officer, EVP, Chief Scientific Officer
Sepp-Lorenzino Laura
CIK: 0001777421
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)1 (20.0%)
Derivative conversions
Awards (A)3 (60.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 1, 2026TSHA
Taysha Gene Therapies, Inc.
AwardDirect21.3K shares- - Apr 28, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirectStock Option (right to buy)
50K shares- - Jun 2, 2025TSHA
Taysha Gene Therapies, Inc.
AwardDirect56.6K shares- - Jan 3, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect9K shares at avg. $12.18$109K - Jan 1, 2025NTLA
Intellia Therapeutics, Inc.
ExerciseDirect3.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 1, 2026 |  TSHA Taysha Gene Therapies, Inc. | Award | 21,335 | - | $0 | Direct |
| Apr 28, 2026 |  LXEO Lexeo Therapeutics, Inc. | Award Stock Option (right to buy) | 50,000 | - | - | Direct |
| Jun 2, 2025 | TSHA Taysha Gene Therapies, Inc. | Award | 56,623 | - | - | Direct |
| Jan 3, 2025 |  NTLA Intellia Therapeutics, Inc. | Sale | 8,966 | $12.18 | $109,206 | Direct |
| Jan 1, 2025 | NTLA Intellia Therapeutics, Inc. | Exercise | 3,500 | - | $0 | Direct |
1-5 of 5 transactions